YouTube Facebook LinkedIn Google+ Twitter Xingrss  

The Coming Wave of Generic Biologics


June 13, 2014 | Matthew Herper examines the market for generic biotech therapies, which have sometimes been seen as more resistant to generic competition than chemically manufactured drugs. Many of the most successful biologics are due to see their patents expire in the near future, including Rituxan and Neulasta, both of which will be open to generic competition in 2015. Herper looks at the few past cases of biotechs going generic to predict which may be vulnerable to a steep loss of market share. Forbes
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.